Literature DB >> 23744584

Prolylcarboxypeptidase promotes angiogenesis and vascular repair.

Gregory N Adams1, Evi X Stavrou, Chao Fang, Alona Merkulova, M Amer Alaiti, Kohsuke Nakajima, Toshifumi Morooka, Sergei Merkulov, Gretchen A Larusch, Daniel I Simon, Mukesh K Jain, Alvin H Schmaier.   

Abstract

Prolylcarboxypeptidase (PRCP) is associated with leanness, hypertension, and thrombosis. PRCP-depleted mice have injured vessels with reduced Kruppel-like factor (KLF)2, KLF4, endothelial nitric oxide synthase (eNOS), and thrombomodulin. Does PRCP influence vessel growth, angiogenesis, and injury repair? PRCP depletion reduced endothelial cell growth, whereas transfection of hPRCP cDNA enhanced cell proliferation. Transfection of hPRCP cDNA, or an active site mutant (hPRCPmut) rescued reduced cell growth after PRCP siRNA knockdown. PRCP-depleted cells migrated less on scratch assay and murine PRCP(gt/gt) aortic segments had reduced sprouting. Matrigel plugs in PRCP(gt/gt) mice had reduced hemoglobin content and angiogenic capillaries by platelet endothelial cell adhesion molecule (PECAM) and NG2 immunohistochemistry. Skin wounds on PRCP(gt/gt) mice had delayed closure and reepithelialization with reduced PECAM staining, but increased macrophage infiltration. After limb ischemia, PRCP(gt/gt) mice also had reduced reperfusion of the femoral artery and angiogenesis. On femoral artery wire injury, PRCP(gt/gt) mice had increased neointimal formation, CD45 staining, and Ki-67 expression. Alternatively, combined PRCP(gt/gt) and MRP-14(-/-) mice were protected from wire injury with less neointimal thickening, leukocyte infiltration, and cellular proliferation. PRCP regulates cell growth, angiogenesis, and the response to vascular injury. Combined with its known roles in blood pressure and thrombosis control, PRCP is positioned as a key regulator of vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744584      PMCID: PMC3750346          DOI: 10.1182/blood-2012-10-460360

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Association between the molecular pathobiology of essential hypertension and thrombotic diseases.

Authors:  T S Edgington
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

2.  A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.

Authors:  Katja A Puttonen; Sárka Lehtonen; Atso Raasmaja; Pekka T Männistö
Journal:  Toxicol In Vitro       Date:  2006-07-14       Impact factor: 3.500

Review 3.  Molecular basis of restenosis and drug-eluting stents.

Authors:  Marco A Costa; Daniel I Simon
Journal:  Circulation       Date:  2005-05-03       Impact factor: 29.690

Review 4.  Normal cutaneous wound healing: clinical correlation with cellular and molecular events.

Authors:  Christian L Baum; Christopher J Arpey
Journal:  Dermatol Surg       Date:  2005-06       Impact factor: 3.398

5.  High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14.

Authors:  M J Hunter; W J Chazin
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

6.  Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator.

Authors:  Zia Shariat-Madar; Fakhri Mahdi; Alvin H Schmaier
Journal:  J Biol Chem       Date:  2002-02-05       Impact factor: 5.157

7.  Recombinant prolylcarboxypeptidase activates plasma prekallikrein.

Authors:  Zia Shariat-Madar; Fakhri Mahdi; Alvin H Schmaier
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

8.  E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients.

Authors:  Yan Zhang; Xiu-mei Hong; Hou-xun Xing; Jian-ping Li; Yong Huo; Xi-ping Xu
Journal:  Chin Med J (Engl)       Date:  2009-10-20       Impact factor: 2.628

9.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

10.  KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation.

Authors:  Sucharita SenBanerjee; Zhiyong Lin; G Brandon Atkins; Daniel M Greif; Ravi M Rao; Ajay Kumar; Mark W Feinberg; Zhiping Chen; Daniel I Simon; F William Luscinskas; Thomas M Michel; Michael A Gimbrone; Guillermo García-Cardeña; Mukesh K Jain
Journal:  J Exp Med       Date:  2004-05-10       Impact factor: 14.307

View more
  24 in total

1.  Physiologic activities of the contact activation system.

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

2.  Ex situ Perfusion of Pancreas for Whole-Organ Transplantation: Is it Safe and Feasible? A Systematic Review.

Authors:  Thomas Prudhomme; Delphine Kervella; Stéphanie Le Bas-Bernardet; Diego Cantarovich; Georges Karam; Gilles Blancho; Julien Branchereau
Journal:  J Diabetes Sci Technol       Date:  2019-08-13

3.  Prolyl carboxypeptidase activity decline correlates with severity and short-term outcome in acute ischemic stroke.

Authors:  Kaat Kehoe; Raf Brouns; Robert Verkerk; Sebastiaan Engelborghs; Peter Paul De Deyn; Dirk Hendriks; Ingrid De Meester
Journal:  Neurochem Res       Date:  2014-11-05       Impact factor: 3.996

4.  Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II.

Authors:  Christoph Maier; Ines Schadock; Philipp K Haber; Jan Wysocki; Minghao Ye; Yashpal Kanwar; Christopher A Flask; Xin Yu; Brian D Hoit; Gregory N Adams; Alvin H Schmaier; Michael Bader; Daniel Batlle
Journal:  J Mol Med (Berl)       Date:  2017-02-03       Impact factor: 4.599

5.  Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).

Authors:  J Wang; A Matafonov; H Madkhali; F Mahdi; D Watson; A H Schmaier; D Gailani; Z Shariat-Madar
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

Review 6.  Antithrombotic potential of the contact activation pathway.

Authors:  Alvin H Schmaier
Journal:  Curr Opin Hematol       Date:  2016-09       Impact factor: 3.284

7.  The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.

Authors:  Lei Duan; Guoguang Ying; Brian Danzer; Ricardo E Perez; Zia Shariat-Madar; Victor V Levenson; Carl G Maki
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

8.  A refined model of the genomic basis for phenotypic variation in vertebrate hemostasis.

Authors:  Ângela M Ribeiro; M Lisandra Zepeda-Mendoza; Mads F Bertelsen; Annemarie T Kristensen; Erich D Jarvis; M Thomas P Gilbert; Rute R da Fonseca
Journal:  BMC Evol Biol       Date:  2015-06-30       Impact factor: 3.260

Review 9.  Ischemia-Reperfusion Injuries Assessment during Pancreas Preservation.

Authors:  Thomas Prudhomme; John F Mulvey; Liam A J Young; Benoit Mesnard; Maria Letizia Lo Faro; Ann Etohan Ogbemudia; Fungai Dengu; Peter J Friend; Rutger Ploeg; James P Hunter; Julien Branchereau
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

Review 10.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.